Mercer Global Advisors
RARE icon

Mercer Global Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mercer Global Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$708K Buy
33,785
+19,820
+142% +$446K ﹤0.01% 1757
2025
Q4 		$321K Buy
13,965
+2,036
+17% +$67K ﹤0.01% 2180
2025
Q3 		$359K Buy
+11,929
New +$358K ﹤0.01% 1967

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Mercer Global Advisors's RARE Position: Q1 2026 in Review

Mercer Global Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 142% in Q1 2026, buying an estimated $446K and bringing the position to 33,785 shares worth $708K. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Mercer Global Advisors first reported a position in RARE in Q3 2025 and has held it in 3 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Mercer Global Advisors held 33,785 shares of Ultragenyx Pharmaceutical worth $708K as of Q1 2026.
  • Mercer Global Advisors bought 19,820 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $446K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #1757 holding.
  • Mercer Global Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.